Introduction {#Sec1}
============

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative but intensive therapy for a variety of hematopoietic disorders, and the number of HSCTs has continued to increase over the last ten years, especially in the elderly population. The outcomes of HSCT have also improved and the number of recipients who achieve long-term survival after HSCT continues to increase. Therefore, the current goal of HSCT is not only curing disease but also maintaining a high quality of life while reducing physical and/or mental distress after HSCT \[[@CR1]--[@CR3]\].

Deconditioning and reduction of physical function are likely to occur after HSCT. Decreased physical activity due to isolation in a protective environment, and the impact of regimen-related toxicity and/or post-transplant complications have been reported as causes for this physical decline \[[@CR4]--[@CR6]\]. Decreases in endurance capacity may result in easy fatigability and loss of muscle strength may cause disabilities.

The purpose of exercise and rehabilitation for patients undergoing HSCT is to prevent deconditioning and recover from decreased physical function. Previous studies have shown the efficacy of rehabilitation in patients undergoing HSCT using a variety of exercise modalities, including aerobic, resistance, and mixed (aerobic and resistance) programs \[[@CR7]--[@CR16]\]. However, functional capacity declines after HSCT, even with exercise therapy \[[@CR8], [@CR10], [@CR12], [@CR17], [@CR18]\]. Thus, identifying the factors related to physical function after HSCT is crucial to establish better preventive and rehabilitative strategies. Some studies have suggested that the decrease in fitness was associated with the fever period and total dose of corticosteroids \[[@CR17]\], while the decrease in strength was associated with the total dose of corticosteroids \[[@CR17], [@CR18]\]. However, in these studies, the sample size was small \[[@CR17]\], and a 6-min walk test was used for the evaluation of fitness \[[@CR17], [@CR18]\] instead of peak oxygen consumption (VO~2~) during cardiopulmonary exercise testing (CPX), which is the gold standard. In addition, certain important factors, such as baseline physical function before HSCT, were not included in these previous analyses \[[@CR17], [@CR18]\]. Thus, the aim of the present study was to explore the factors associated with post-HSCT leg extension muscle strength and cardiopulmonary fitness evaluated with peak VO~2~.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was a retrospective cohort study performed at the Keio University Hospital in Tokyo, Japan. The study protocol was approved by the Ethics Committee of Keio University School of Medicine (No. 20120072).

Participants {#Sec4}
------------

Of 146 consecutive patients who underwent allogeneic HSCT from April 2008 to March 2013, 108 patients satisfied the inclusion and exclusion criteria. Inclusion criteria were aged 18 years or older on the day of HSCT, underwent allogeneic HSCT at Keio University Hospital, and were evaluated for leg extension muscle strength and/or cardiopulmonary fitness using CPX at both pre- and post-HSCT. Patients were excluded if they developed any severe physical dysfunctions that could affect muscular strength and fitness evaluation, such as joint contractures and/or severe joints pain of the lower extremities; avascular necrosis of the femur head; painful metastatic bone lesions; bone lesions requiring limited weight bearing; severe heart failure (New York Heart Association, III--IV); or required assistance for basic activities of daily living. Patients were also excluded from the study if they could not receive leg extension muscle strength and/or cardiopulmonary fitness evaluations due to acute somatic conditions (such as infection, fever, or acute bleeding) at the time of evaluation. After excluding these patients and those with missing data for the analyses, 88 patients were enrolled in the study.

Physical therapy {#Sec5}
----------------

All patients participated in a rehabilitation program 5 days a week before, during, and after HSCT. At the rehabilitation gym, the patients received physical therapy including stretching of the neck, trunk, and extremities; resistance exercise for the muscles of the trunk and upper and lower extremities; aerobic exercise using a treadmill or cycle ergometer (up to 30 min) with an aim of approximately 60% of heart rate (HR) reserve calculated according to the Karvonen method \[[@CR19]\]: (HR~peak~ during CPX − HR~rest~) × 60 %  + HR~rest~; and walking and stair training. An infrared ear/finger clip heart rate sensor was used for monitoring the heart rates during exercise. The content and intensity of the exercise were adjusted according to the physical condition of each patient. From the start of conditioning to neutrophil engraftment and other periods of neutropenia, such as those caused by additional chemotherapy before HSCT, a similar exercise program was carried out in the protective environment or the ward. However, during this period, walking tended to be more frequent than exercise on the ergometer and treadmill due to the patients' physical conditions and lack of equipment. As such, the location of exercise was changed from the ward to the rehabilitation gym after HSCT when permission from the attending hematologists was obtained after achieving sustained neutrophil engraftment.

Treatment of acute graft-versus-host disease {#Sec6}
--------------------------------------------

Primary treatment of acute graft-versus-host disease (GVHD) was provided according to its grades \[[@CR20]\]. Patients with grade I acute GVHD were treated with topical steroids. Patients with grade II--IV acute GVHD were treated with 1.0--2.0 mg/kg/day of (methyl-)prednisolone, while grade II acute GVHD limited to the skin was treated with hydrocortisone infusion and/or 0.5--1.0 mg/kg/day of (methyl-)prednisolone. Once patients responded, the dose of steroid started being tapered 10% of initial dose every 5 days.

Multidisciplinary team approaches {#Sec7}
---------------------------------

For all the participants, team conferences with multidisciplinary members including registered dieticians, psychiatrists, dentists, transplant coordinators, pharmacists, physical therapists, and physiatrists were held every week or once every 2 weeks.

Evaluation of strength and cardiopulmonary fitness {#Sec8}
--------------------------------------------------

Muscle strength and cardiopulmonary fitness evaluations were performed on each patient twice: before the HSCT conditioning regimen (pre) and at the initiation of gym-based training when hematopoietic recovery was obtained after HSCT (post).Leg extension muscle strength

To evaluate leg extension muscle strength, an isokinetic test of peak leg extension torque was performed with a recumbent cycle ergometer at 50 rpm (Strength Ergo 240™; Mitsubishi Electric Corporation, Tokyo, Japan). This test has excellent test-retest reliability and sufficient validity against a conventional isokinetic dynamometer \[[@CR21], [@CR22]\]. The backrest was adjusted to a reclining position (110°) and the seat position was adjusted so that the patient's knee was flexed 20° when at maximal extension. The trunk of the body was fixed at the shoulders with seatbelts. The peak torque values for five revolutions were measured and averaged. Each patient performed the test twice and the higher value was adopted. The adopted peak leg extension torque was adjusted to a value per kg of body weight.b)Cardiopulmonary fitness

The CPX was performed to the symptom-limited maximum using an upright, servo motor type, cycle ergometer (Strength Ergo 8™; Mitsubishi Electric Corporation, Tokyo, Japan). For each patient, breath-by-breath VO~2~ was measured during the cycling exercise at 60 rpm through a face mask using an expired gas analyzer (AE-300S™; Minato Medical Science Company Limited, Tokyo, Japan or Vmax 29™; SensorMedics Corporation, Yorba Linda, CA, USA). Both systems consist of a dumbbell type paramagnetic oxygen analyzer and infrared carbon dioxide analyzer, and both systems' reliability and validity have been confirmed \[[@CR23]--[@CR26]\]. After 2 min of rest and 2 min of unloaded pedaling, the exercise load was increased by 10--15 W per min using a ramp protocol. Exercise was continued up to the limits of tolerance indicated by reduced pedaling rotation (despite being encouraged), unbearable shortness of breath, and/or a plateau in VO~2~ or HR response. Peak VO~2~ (mL/kg/min) was measured as the average value obtained during the last 30 s of the incremental test as an index of endurance capacity. Peak VO~2~ was adjusted to a value per kilogram of body weight for the analyses.

Data collection {#Sec9}
---------------

Demographic information and clinical data were collected via the medical charts. Demographic data included age, sex, underlying diseases (leukemia, lymphoma, multiple myeloma, or aplastic anemia), conditioning regimen (myeloablative conditioning or reduced-intensity conditioning, total body irradiation, or non-total body irradiation), serum albumin level, hemoglobin level, and Karnofsky performance status (KPS) score \[[@CR27]\] before HSCT. The interval between pre- and post-evaluation, number of days from HSCT to neutrophil engraftment, grades of acute GVHD \[[@CR20]\], and infections (cytomegalovirus disease, bacterial infection, and invasive pulmonary aspergillosis) were also collected as clinical data.

Analyses {#Sec10}
--------

Descriptive analyses were performed on the patients' characteristics. Pre- and post-differences for leg extension torque and peak VO~2~ were examined using a paired *t* test.

To clarify the factors related to leg extension torque and peak VO~2~ post-HSCT, we analyzed their relationships with several variables at baseline and during the clinical course via correlational analyses or comparison analyses. For continuous variables such as age, serum albumin level, and hemoglobin level, correlations between these variables and post-HSCT leg extension torque or post-HSCT peak VO~2~ were analyzed using the Pearson's product moment correlation coefficient or the Spearman's correlation coefficient, depending on the type of variable. With regard to the categorical variables such as sex and infectious complications, post-HSCT leg extension torque and post-HSCT peak VO~2~ were divided into two groups according to the category and were then compared using an independent *t* test.

Stepwise multiple regression analyses for post-HSCT leg extension torque and post-HSCT peak VO~2~ were performed using age, sex, and the variables with a *p* value \< 0.2 in the above correlational or comparison analyses.

All statistical analyses were performed using IBM SPSS version 23 (IBM Corporation, Armonk, NY, USA), and a *p* value \< 0.05 was considered to be statistically significant.

Results {#Sec11}
=======

Patients' characteristics are shown in Table [1](#Tab1){ref-type="table"}. Both leg extension torque and peak VO~2~ significantly decreased after HSCT (*p* \< 0.001 for both; Fig. [1](#Fig1){ref-type="fig"}). Of note, peak VO~2~ was evaluated in 67 of the 88 patients at both pre- and post-HSCT; 12 patients pre-HSCT and 16 patients post-HSCT could not be evaluated due to poor general condition and/or limited time for evaluation.Table 1Patient characteristics (*n* = 88)Age, years44.5 (30--52)Sex, male/female46/42Underlying diseases Acute myeloid leukemia17 (19.3) Acute lymphoblastic leukemia19 (21.6) Myelodysplastic syndrome12 (13.6) Chronic myelogenous leukemia5 (5.7) Other leukemia3 (3.4) Myeloproliferative neoplasms2 (2.3) Aplastic anemia8 (9.1) Hodgkin/non-Hodgkin lymphoma12 (13.6) Multiple myeloma10 (11.4)Prior allogeneic HSCT (stem cell source and type of donor) None84 (95.5) Bone marrow/PBSCs from an HLA-identical sibling3 (3.4) Bone marrow from an unrelated donor1 (1.1)Stem cell source and type of donor Bone marrow/PBSCs from an HLA-identical sibling21 (23.9) Bone marrow from an HLA-mismatched family member1 (1.1) Bone marrow from an unrelated donor59 (67.0) Cord blood from an unrelated donor7 (8.0)Conditioning Myeloablative59 (67.0) Reduced-intensity29 (33.0) Total body irradiation-based64 (72.7) Non-total body irradiation24 (27.3)Karnofsky performance status score before HSCT100 (90--100)Number of patients achieving engraftment88 (100)Grades of acute graft-versus-host disease 035 (39.8) I18 (20.5) II28 (31.8) III5 (5.7) IV2 (2.3)Infections Cytomegalovirus disease16 (18.2) Bacterial infection54 (61.4) Invasive pulmonary aspergillosis4 (4.5)Interval between pre- and post-transplant evaluation69 (61--80) Interval between pre-evaluation and transplantation27 (25--30) Interval between transplantation and post-evaluation41 (33--50)Length of hospital stay121 (97--161)Data are presented as median (interquartile range) or number (%)*HSCT* hematopoietic stem cell transplantation, *PBSC* peripheral blood stem cell, *HLA* human leukocyte antigenFig. 1Comparison of leg extension torque (**a**) and peak oxygen consumption (VO~2~) (**b**) pre- and post-hematopoietic stem cell transplantation (HSCT)The post-HSCT values of both variables significantly decreased compared to the pre-HSCT values. Error bars indicate standard deviation

In the correlational or comparison analyses, variables with *p* \< 0.2 were age, sex, serum albumin, pre-HSCT leg extension torque, pre-HSCT peak VO~2~, KPS score, pre- and post-evaluation interval, grades of acute GVHD, leukemia, aplastic anemia, cytomegalovirus disease, and invasive pulmonary aspergillosis for post-HSCT leg extension torque; and age, serum albumin, pre-HSCT leg extension torque, and pre-HSCT peak VO~2~ for post-HSCT peak VO~2~ (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). We included age, sex, and these variables with *p* \< 0.2 in the multiple regression models. Multiple regression analysis for post-HSCT leg extension torque revealed that lower pre-HSCT leg extension torque, higher grades of acute GVHD, older age, and longer interval between pre- and post-evaluations were significant factors associated with reduced post-HSCT leg extension torque (Table [4](#Tab4){ref-type="table"}(a)). Conversely, only lower pre-HSCT peak VO~2~ was significantly associated with reduced post-HSCT peak VO~2~ (Table [4](#Tab4){ref-type="table"}(b)).Table 2Correlation coefficients between continuous variables and leg extension torque and peak VO~2~ post-hematopoietic stem cell transplantationVariablePost-HSCTLeg extension torque (*n* = 88)Peak VO~2~ (*n* = 67)Correlation Coefficient*p* valueCorrelation Coefficient*p* valuePre-HSCTAge, years− 0.55\< 0.001− 0.300.013Serum albumin, g/dL0.160.1310.190.127Hemoglobin, g/dL− 0.080.444− 0.060.648Leg extension torque, N·m/kg0.71\< 0.0010.320.008Peak VO~2~, mL/kg/min0.240.0380.50\< 0.001Karnofsky performance status score0.140.1810.050.695Pre- and post-evaluation interval, days− 0.37\< 0.0010.070.578Duration from HSCT to neutrophil engraftment, days− 0.010.935− 0.010.921Grades of acute GVHD− 0.350.0010.040.972*VO*~*2*~ oxygen consumption, *HSCT* hematopoietic stem cell transplantation, *GVHD* graft-versus-host diseaseTable 3Comparison of variables and post-hematopoietic stem cell transplantation leg extension torque and peak VO~2~ via independent *t* testPost-HSCTLeg extension torque, N·m (*n* = 88)Peak VO~2~, mL/kg/min (*n* = 67)VariableYesNo*p* valueYesNo*p* valueSex (Yes, male; No, female)1.65 ± 0.521.40 ± 0.370.01119.66 ± 4.1719.54 ± 4.200.905Leukemia1.45 ± 0.481.67 ± 0.440.04419.55 ± 4.2819.70 ± 3.970.895Lymphoma1.60 ± 0.511.52 ± 0.470.57818.77 ± 3.2719.73 ± 4.280.522Multiple myeloma1.63 ± 0.431.51 ± 0.480.47721.20 ± 5.0319.38 ± 4.020.248Aplastic anemia1.82 ± 0.331.50 ± 0.480.06518.96 ± 3.2019.65 ± 4.240.724Myeloablative conditioning1.57 ± 0.481.46 ± 0.460.31119.48 ± 4.2619.85 ± 4.020.736Total body irradiation1.57 ± 0.481.42 ± 0.440.21619.40 ± 4.2820.14 ± 3.850.523Cytomegalovirus disease1.37 ± 0.571.56 ± 0.450.19019.90 ± 2.3719.56 ± 4.330.841Bacterial infection1.49 ± 0.491.57 ± 0.450.44019.45 ± 4.0819.80 ± 4.320.735Invasive pulmonary aspergillosis1.14 ± 0.451.54 ± 0.470.14518.55 ± 2.6219.63 ± 4.200.720Data are presented as mean ± standard deviation*VO*~*2*~ oxygen consumption, *HSCT* hematopoietic stem cell transplantationTable 4Multiple regression analysis of post-hematopoietic stem cell transplantation muscle strength and cardiopulmonary fitnessUnstandardized coefficientStandard errorStandardized coefficientt*p* valueA. Model for post-HSCT leg extension torque (*n* = 88)^a^ Pre-HSCT leg extension torque0.6010.0820.5197.345\< 0.001 Grades of acute GVHD− 0.1010.032− 0.222− 3.1430.002 Age− 0.0090.003− 0.225− 2.9170.005 Pre- and post-evaluation interval− 0.0070.002− 0.229− 3.2410.002 Constant1.4050.2755.104\< 0.001B. Model for post-HSCT peak VO~2~ (*n* = 67)^b^ Pre-HSCT peak VO~2~0.4570.0980.5024.684\< 0.001 Constant9.1742.2694.043\< 0.001*HSCT* hematopoietic stem cell transplantation, *GVHD* graft-versus-host disease, *VO*~*2*~ oxygen consumption^a^*F* (4, 72) = 40.86, *p* \< 0.001, adjusted *R*^2^ = 0.677^b^*F* (1, 65) = 21.94, *p* \< 0.001, adjusted *R*^2^ = 0.252

Discussion {#Sec12}
==========

This study identified the factors associated with post-treatment lower limb muscle strength and cardiopulmonary fitness in 88 patients who underwent allogenic HSCT. Both leg extension torque and peak VO~2~ significantly reduced after HSCT, and the pre-transplant values of peak VO~2~ and leg extension torque were significantly related to their respective post-transplant values. Post-HSCT leg extension torque was also significantly associated with grades of acute GVHD, age, and pre- and post-evaluation interval.

The effect of pre-HSCT physical status on post-HSCT status has not been well understood as previous studies did not include pre-transplant physical status into their analyses \[[@CR17], [@CR18]\]. Thus, to our knowledge, our study was the first to reveal that post-HSCT leg extension torque and peak VO~2~ were strongly associated with each of their pre-HSCT variables, respectively. These findings suggest that the higher the physical function before HSCT, the higher the physical function after HSCT. Previous studies showed that physical fitness was lower in patients before HSCT than in healthy subjects \[[@CR28]\], and low functional capacity was associated with high mortality \[[@CR29], [@CR30]\] and longer hospital stay \[[@CR30]\]. Considering these findings and those of the present study, maximizing physical capacity before HSCT could lead to better functional outcomes, as well as reduce the length of hospital stay and mortality risk.

Regarding leg extension torque, a significant negative correlation between the grades of acute GVHD and leg extension torque after HSCT was found. There are two possible reasons for this finding. First, acute GVHD is a significant factor that influences substantial deterioration in nutritional status during HSCT and in the early period after HSCT \[[@CR31]\]. Second, it is known that the decrease in strength is associated with total dose of corticosteroids \[[@CR17], [@CR18]\]. In general, corticosteroids are administered to patients with grade II or higher GVHD and are often used at lower doses in grade II than in grade III or IV disease \[[@CR32], [@CR33]\]. Thus, steroidal muscle atrophy may have been involved in muscle weakness, in addition to exhaustion and malnutrition due to GVHD itself. Considering the relationship between the dose of corticosteroids and the severity of GVHD, our findings are consistent with previous studies that showed a relationship between muscle strength and corticosteroids dose \[[@CR17], [@CR18]\]. With regard to age, it has been reported that loss of muscle strength with aging \[[@CR34]--[@CR37]\] may be accelerated by the failure of muscle mass recovery after temporary disuse-induced muscle atrophy \[[@CR35]\]. Therefore, the finding that the older the patients were, the poorer the muscle strength recovery was during HSCT is quite reasonable. The most logical answer to the question of why the interval between the evaluations was associated with reduced post-HSCT muscular strength is that the patients with longer evaluation intervals might have been in an unstable condition and stayed in the ward for a longer period to prevent infection; these conditions likely led to lower activity levels and might have weakened muscle strength.

Multiple regression analysis revealed that only pre-HSCT peak VO~2~ was associated with post-HSCT peak VO~2~. This indicates that the influence of exercise capacity before HSCT has the strongest effect compared with other factors. A relationship between hemoglobin values and exercise capacity was previously reported in healthy individuals \[[@CR38], [@CR39]\] and patients with various pathological conditions \[[@CR40]--[@CR43]\], including those requiring HSCT \[[@CR18]\]. Although the findings from these previous studies suggested that hemoglobin level influences fitness level, we showed that the hemoglobin level before HSCT did not influence post-HSCT fitness.

The clinical implication drawn from the study is that maximizing the physical function before the HSCT is the key to preserve the function after the HSCT. Self-administered exercise before, during, and after HSCT was shown to be beneficial \[[@CR12]\]. Furthermore, the supervised-individualized exercise before the HSCT was proven to be feasible \[[@CR44]\]. The findings of these reports and ours suggest that it may be worth doing physical exercise before HSCT, although a well-designed randomized controlled trial is clearly warranted to ascertain the value of pre-HSCT physical exercise intervention.

There were limitations in this study. The study was conducted at a single facility. Only patients who could be evaluated for leg extension muscle strength and cardiopulmonary fitness using CPX were analyzed; therefore, those in poor general condition were not included. In addition, precise information about the dose of steroids and exercise adherence could not be obtained and were not included in the analyses because of the retrospective nature of the study. A prospective study including patients with various characteristics is necessary to increase the generalizability of our findings.

In conclusion, our findings suggest that improving muscular strength and cardiopulmonary fitness before receiving HSCT is important for maintaining physical function after HSCT treatment. Additionally, we emphasize the importance of commencing rehabilitation earlier before HSCT. Our study also suggests that careful consideration should be paid to lower limb muscle strength, especially in elderly individuals who are developing acute GVHD and those who are staying in a protective environment long-term.
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